BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 7751879)

  • 1. Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma.
    Nadali G; Vinante F; Stein H; Todeschini G; Tecchio C; Morosato L; Chilosi M; Menestrina F; Kinney MC; Greer JP
    J Clin Oncol; 1995 Jun; 13(6):1355-60. PubMed ID: 7751879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients.
    Zinzani PL; Pileri S; Bendandi M; Buzzi M; Sabattini E; Ascani S; Gherlinzoni F; Magagnoli M; Albertini P; Tura S
    J Clin Oncol; 1998 Apr; 16(4):1532-7. PubMed ID: 9552063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD30 ligand in lymphoma patients with CD30+ tumors.
    Younes A; Consoli U; Snell V; Clodi K; Kliche KO; Palmer JL; Gruss HJ; Armitage R; Thomas EK; Cabanillas F; Andreeff M
    J Clin Oncol; 1997 Nov; 15(11):3355-62. PubMed ID: 9363866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis.
    Nadali G; Vinante F; Ambrosetti A; Todeschini G; Veneri D; Zanotti R; Meneghini V; Ricetti MM; Benedetti F; Vassanelli A
    J Clin Oncol; 1994 Apr; 12(4):793-7. PubMed ID: 8151321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis.
    Visco C; Nadali G; Vassilakopoulos TP; Bonfante V; Viviani S; Gianni AM; Federico M; Luminari S; Peethambaram P; Witzig TE; Pangalis G; Cabanillas F; Medeiros LJ; Sarris AH; Pizzolo G
    Eur J Haematol; 2006 Nov; 77(5):387-94. PubMed ID: 16879607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients.
    Zinzani PL; Bendandi M; Martelli M; Falini B; Sabattini E; Amadori S; Gherlinzoni F; Martelli MF; Mandelli F; Tura S; Pileri SA
    J Clin Oncol; 1996 Mar; 14(3):955-62. PubMed ID: 8622045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age-dependent changes of serum soluble CD30 concentration in children.
    Chrul S; Polakowska E
    Pediatr Transplant; 2011 Aug; 15(5):515-8. PubMed ID: 21672104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble CD30 serum levels in atopic dermatitis and bronchial asthma and its relationship with disease severity in pediatric age.
    Heshmat NM; El-Hadidi ES
    Pediatr Allergy Immunol; 2006 Jun; 17(4):297-303. PubMed ID: 16771784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease.
    Gause A; Pohl C; Tschiersch A; Da Costa L; Jung W; Diehl V; Hasenclever D; Pfreundschuh M
    Blood; 1991 May; 77(9):1983-8. PubMed ID: 1850308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: relationship with disease activity and clinical stage.
    Pizzolo G; Vinante F; Chilosi M; Dallenbach F; Josimovic-Alasevic O; Diamantstein T; Stein H
    Br J Haematol; 1990 Jun; 75(2):282-4. PubMed ID: 2164839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
    Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anaplastic large cell lymphoma (CD30+/Ki-1+). Analysis of 35 cases followed at GISL centres.
    Longo G; Federico M; Pieresca C; Avanzini P; Iannitto E; Di Prisco AU; Baldini L; Brugiatelli M; Clò V; Bevini M
    Eur J Cancer; 1995 Oct; 31A(11):1763-7. PubMed ID: 8541096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble CD30: a possible serum tumor marker for primary effusion lymphoma.
    Michai M; Goto H; Hattori S; Vaeteewoottacharn K; Wongkham C; Wongkham S; Okada S
    Asian Pac J Cancer Prev; 2012; 13(10):4939-41. PubMed ID: 23244086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble CD30 and cyclosporine in severe atopic dermatitis.
    Caproni M; Salvatore E; Cardinali C; Brazzini B; Fabbri P
    Int Arch Allergy Immunol; 2000 Apr; 121(4):324-8. PubMed ID: 10828723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD30 molecule (Ki-1 Ag): more than just a marker of CD30+ lymphoma.
    Pizzolo G; Romagnani S
    Haematologica; 1995; 80(4):357-66. PubMed ID: 7590507
    [No Abstract]   [Full Text] [Related]  

  • 16. [Dipeptidyl aminopeptidase-IV as a histochemical marker of differential diagnosis of large cell anaplastic CD30+-lymphoma and Hodgkin's disease].
    Raĭkhlin NT; Bukaeva IA; Probatova NA; Smirnova EA; Pavlovskaia AI; Tupitsyn NN; Sholokhova EN
    Arkh Patol; 2000; 62(4):3-8. PubMed ID: 10971865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary Ki-1 anaplastic large-cell lymphoma in adults: clinical characteristics and therapeutic outcome.
    Shulman LN; Frisard B; Antin JH; Wheeler C; Pinkus G; Magauran N; Mauch P; Nobles E; Mashal R; Canellos G
    J Clin Oncol; 1993 May; 11(5):937-42. PubMed ID: 8387578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells.
    Hirsch B; Hummel M; Bentink S; Fouladi F; Spang R; Zollinger R; Stein H; Dürkop H
    Am J Pathol; 2008 Feb; 172(2):510-20. PubMed ID: 18187570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary cutaneous CD30 positive T-cell lymphoproliferative disorders with aberrant expression of PAX5: report of three cases.
    Hagiwara M; Tomita A; Takata K; Shimoyama Y; Yoshino T; Tomita Y; Nakamura S
    Pathol Int; 2012 Apr; 62(4):264-70. PubMed ID: 22449230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features and treatment outcome for children with CD30+ large-cell non-Hodgkin's lymphoma.
    Sandlund JT; Pui CH; Santana VM; Mahmoud H; Roberts WM; Morris S; Raimondi S; Ribeiro R; Crist WM; Lin JS
    J Clin Oncol; 1994 May; 12(5):895-8. PubMed ID: 8164039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.